Dr. Reddy's LaboratoriesRDY
紐約證券 · USD
14.91
+0.38
(+2.62%)
收盤 11/07 04:59 (UTC+8)
11/07 04:59 (UTC+8)
Dr. Reddy's LaboratoriesRDY
14.91
+0.38
(+2.62%)
財務數據
損益表
- 767.27
- 801.62
- 835.86
- 850.60
- 854.52
- 880.51
- 872.68
- 751.62
- 807.05
- 867.08
- 8.33
- 4.48
- 4.27
- 1.76
- 0.46
- 3.04
- -0.89
- -13.87
- 7.37
- 7.44
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2026/Q3 | 2026/Q2 | 2026/Q1 | 2025/Q4 | 2025/Q3 | 2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | |
營業收入淨額 | 86,708,000 | 80,705,000 | 75,162,000 | 87,268,000 | 88,051,000 | 85,452,000 | 85,060,000 | 83,586,000 | 80,162,000 | 76,727,000 |
營業成本 | 41,504,000 | 43,165,000 | 32,127,000 | 40,462,000 | 39,911,000 | 36,825,000 | 28,500,000 | 34,534,000 | 32,393,000 | 30,383,000 |
營業毛利 | 45,204,000 | 37,540,000 | 43,035,000 | 46,806,000 | 48,140,000 | 48,627,000 | 56,560,000 | 49,052,000 | 47,769,000 | 46,344,000 |
營業費用 | 32,398,000 | 34,507,000 | 42,206,000 | 32,476,000 | 29,965,000 | 31,785,000 | 40,360,000 | 30,344,000 | 29,724,000 | 28,802,000 |
研發費用 | 5,235,000 | 5,766,000 | - | 6,149,000 | 6,202,000 | 6,244,000 | 7,258,000 | 6,658,000 | 7,271,000 | 6,193,000 |
推銷及管理費用 | 28,075,000 | 26,096,000 | 14,468,000 | 26,918,000 | 26,436,000 | 23,181,000 | 14,006,000 | 24,117,000 | 23,007,000 | 20,887,000 |
非經常性項目費用 | - | - | - | - | - | - | - | - | - | - |
其他營業費用 | -912,000 | -79,000 | 22,167,000 | -591,000 | -2,673,000 | -106,000 | 21,807,000 | -431,000 | -554,000 | -82,000 |
營業利益 | 12,806,000 | 3,033,000 | 829,000 | 14,330,000 | 18,175,000 | 16,842,000 | 16,200,000 | 18,708,000 | 18,045,000 | 17,542,000 |
其他收入及費用 | - | - | - | - | - | - | - | - | - | - |
利息費用 | 1,248,000 | 1,255,000 | 1,057,000 | 944,000 | 907,000 | 830,000 | 656,000 | 818,000 | 757,000 | 598,000 |
稅前純益 | 12,277,000 | 5,526,000 | 1,997,000 | 15,429,000 | 18,350,000 | 19,047,000 | 20,052,000 | 18,742,000 | 19,167,000 | 18,821,000 |
所得稅 | 3,143,000 | 1,178,000 | -216,000 | 3,533,000 | 4,082,000 | 4,951,000 | 4,185,000 | 4,704,000 | 5,752,000 | 4,901,000 |
稅後純益 | 9,250,000 | 4,435,000 | 2,209,000 | 12,098,000 | 14,372,000 | 14,178,000 | 15,933,000 | 14,133,000 | 12,553,000 | 13,920,000 |
基本每股稅後盈餘(元) | 11.11 | 5.32 | 2.65 | 14.53 | 17.26 | 17.04 | 19.12 | 16.96 | 75.35 | 83.60 |
稀釋每股稅後盈餘(元) | 11.10 | 5.32 | 2.65 | 14.52 | 17.25 | 17.02 | 19.10 | 16.94 | 75.25 | 83.45 |
基本平均股數(千股) | 832583.00 | 833646.00 | 833584.00 | 832622.00 | 832676.00 | 832042.00 | 833315.00 | 833313.00 | 166595.00 | 166507.00 |
稀釋平均股數(千股) | 833333.00 | 833646.00 | 833584.00 | 833195.00 | 833159.00 | 833019.00 | 834188.00 | 834297.00 | 166817.00 | 166806.00 |
還原基本每股稅後盈餘(元) | 11.11 | 5.32 | 2.65 | 14.53 | 17.26 | 17.04 | 19.12 | 16.96 | 15.07 | 16.72 |
還原稀釋每股稅後盈餘(元) | 11.10 | 5.32 | 2.65 | 14.52 | 17.25 | 17.02 | 19.10 | 16.94 | 15.05 | 16.69 |
還原基本平均股數(千股) | 832,583 | 833,646 | 833,584 | 832,622 | 832,676 | 832,042 | 833,315 | 833,313 | 832,979 | 832,535 |
還原稀釋平均股數(千股) | 833,333 | 833,646 | 833,584 | 833,195 | 833,159 | 833,019 | 834,188 | 834,297 | 834,086 | 834,032 |
EBITDA(千元) | 18,910,000 | 12,240,000 | 8,626,000 | 21,788,000 | 24,412,000 | 24,724,000 | 25,328,000 | 24,374,000 | 23,037,000 | 23,229,000 |